Annual Revenue
$464.28 K
+$238.08 K+105.25%
31 August 2024
Summary:
Lexaria Bioscience annual revenue is currently $464.28 thousand, with the most recent change of +$238.08 thousand (+105.25%) on 31 August 2024. During the last 3 years, it has fallen by -$258.42 thousand (-35.76%). LEXX annual revenue is now -65.81% below its all-time high of $1.36 million, reached on 31 October 2012.LEXX Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$84.00 K
$0.000.00%
31 August 2024
Summary:
Lexaria Bioscience quarterly revenue is currently $84.00 thousand, unchanged on 31 August 2024. Over the past year, it has dropped by -$67.30 thousand (-44.48%). LEXX quarterly revenue is now -83.01% below its all-time high of $494.50 thousand, reached on 31 July 2012.LEXX Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$464.30 K
+$53.30 K+12.97%
31 August 2024
Summary:
Lexaria Bioscience TTM revenue is currently $464.30 thousand, with the most recent change of +$53.30 thousand (+12.97%) on 31 August 2024. Over the past year, it has increased by +$184.60 thousand (+66.00%). LEXX TTM revenue is now -70.40% below its all-time high of $1.57 million, reached on 30 April 2013.LEXX TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LEXX Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +105.3% | -44.5% | +66.0% |
| 3 y3 years | -35.8% | +504.3% | +5.3% |
| 5 y5 years | +108.6% | +715.5% | +120.5% |
LEXX Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -35.8% | +105.3% | -44.5% | +504.3% | -35.8% | +164.9% |
| 5 y | 5 years | -35.8% | +108.6% | -71.6% | +715.5% | -43.8% | +164.9% |
| alltime | all time | -65.8% | +3058.3% | -83.0% | +109.8% | -70.4% | +218.3% |
Lexaria Bioscience Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Aug 2024 | $464.28 K(+105.3%) | $84.00 K(0.0%) | $464.30 K(+13.0%) |
| May 2024 | - | $84.00 K(-42.1%) | $411.00 K(+1.6%) |
| Feb 2024 | - | $145.00 K(-4.2%) | $404.70 K(+44.7%) |
| Nov 2023 | - | $151.30 K(+392.8%) | $279.70 K(+23.7%) |
| Aug 2023 | $226.20 K(-11.4%) | $30.70 K(-60.5%) | $226.10 K(-26.2%) |
| May 2023 | - | $77.70 K(+288.5%) | $306.50 K(-6.7%) |
| Feb 2023 | - | $20.00 K(-79.5%) | $328.50 K(-3.2%) |
| Nov 2022 | - | $97.70 K(-12.1%) | $339.20 K(+32.8%) |
| Aug 2022 | $255.40 K(-64.7%) | $111.10 K(+11.4%) | $255.40 K(+45.7%) |
| May 2022 | - | $99.70 K(+224.8%) | $175.30 K(-37.3%) |
| Feb 2022 | - | $30.70 K(+120.9%) | $279.70 K(-36.6%) |
| Nov 2021 | - | $13.90 K(-55.2%) | $441.00 K(-39.0%) |
| Aug 2021 | $722.70 K(+88.0%) | $31.00 K(-84.8%) | $722.80 K(-12.4%) |
| May 2021 | - | $204.10 K(+6.3%) | $825.50 K(+25.5%) |
| Feb 2021 | - | $192.00 K(-35.1%) | $657.80 K(+30.7%) |
| Nov 2020 | - | $295.70 K(+121.2%) | $503.30 K(+131.0%) |
| Aug 2020 | $384.50 K(+72.7%) | $133.70 K(+267.3%) | $217.90 K(+4.1%) |
| May 2020 | - | $36.40 K(-2.9%) | $209.30 K(-10.1%) |
| Feb 2020 | - | $37.50 K(+264.1%) | $232.80 K(+10.5%) |
| Nov 2019 | - | $10.30 K(-91.8%) | $210.60 K(-5.3%) |
| Aug 2019 | $222.60 K(-48.6%) | $125.10 K(+108.8%) | $222.50 K(+14.8%) |
| May 2019 | - | $59.90 K(+291.5%) | $193.80 K(-29.3%) |
| Feb 2019 | - | $15.30 K(-31.1%) | $274.20 K(-36.4%) |
| Nov 2018 | - | $22.20 K(-77.0%) | $430.90 K(-0.6%) |
| Aug 2018 | $433.30 K(+581.3%) | $96.40 K(-31.3%) | $433.30 K(+24.0%) |
| May 2018 | - | $140.30 K(-18.4%) | $349.50 K(+46.5%) |
| Feb 2018 | - | $172.00 K(+599.2%) | $238.50 K(+201.5%) |
| Nov 2017 | - | $24.60 K(+95.2%) | $79.10 K(+24.2%) |
| Aug 2017 | $63.60 K(+56.3%) | $12.60 K(-57.0%) | $63.70 K(+6.7%) |
| May 2017 | - | $29.30 K(+132.5%) | $59.70 K(+63.1%) |
| Feb 2017 | - | $12.60 K(+37.0%) | $36.60 K(-6.6%) |
| Nov 2016 | - | $9200.00(+7.0%) | $39.20 K(-3.9%) |
| Aug 2016 | $40.70 K | $8600.00(+38.7%) | $40.80 K(+10.9%) |
| May 2016 | - | $6200.00(-59.2%) | $36.80 K(-2.6%) |
| Feb 2016 | - | $15.20 K(+40.7%) | $37.80 K(+48.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2015 | - | $10.80 K(+134.8%) | $25.50 K(+73.5%) |
| Aug 2015 | $14.70 K(-98.9%) | $4600.00(-36.1%) | $14.70 K(-89.9%) |
| May 2015 | - | $7200.00(+148.3%) | $146.00 K(-52.4%) |
| Feb 2015 | - | $2900.00(-97.9%) | $306.60 K(-178.1%) |
| July 2014 | - | $135.90 K(-19.0%) | -$392.60 K(+41.7%) |
| Apr 2014 | - | $167.80 K(+4.8%) | -$277.00 K(+44.7%) |
| Jan 2014 | - | $160.10 K(-118.7%) | -$191.40 K(<-9900.0%) |
| Oct 2013 | - | -$856.40 K(-440.5%) | $0.00(-100.0%) |
| July 2013 | - | $251.50 K(-0.7%) | $1.33 M(-15.5%) |
| Apr 2013 | - | $253.40 K(-27.9%) | $1.57 M(+7.4%) |
| Jan 2013 | - | $351.50 K(-25.1%) | $1.46 M(+7.5%) |
| Oct 2012 | $1.36 M(+19.8%) | $469.00 K(-5.2%) | $1.36 M(+18.5%) |
| July 2012 | - | $494.50 K(+241.3%) | $1.15 M(+17.0%) |
| Apr 2012 | - | $144.90 K(-41.9%) | $978.80 K(-12.7%) |
| Jan 2012 | - | $249.40 K(-2.9%) | $1.12 M(-1.1%) |
| Oct 2011 | $1.13 M(+212.8%) | $256.80 K(-21.6%) | $1.13 M(+12.3%) |
| July 2011 | - | $327.70 K(+13.9%) | $1.01 M(+25.5%) |
| Apr 2011 | - | $287.60 K(+9.8%) | $804.70 K(+44.4%) |
| Jan 2011 | - | $262.00 K(+97.6%) | $557.40 K(+53.8%) |
| Oct 2010 | $362.50 K(-14.1%) | $132.60 K(+8.2%) | $362.50 K(+11.2%) |
| July 2010 | - | $122.50 K(+204.0%) | $325.90 K(-2.1%) |
| Apr 2010 | - | $40.30 K(-39.9%) | $332.90 K(-7.5%) |
| Jan 2010 | - | $67.10 K(-30.1%) | $359.80 K(-14.7%) |
| Oct 2009 | $422.00 K(-53.2%) | $96.00 K(-25.9%) | $422.00 K(-0.4%) |
| July 2009 | - | $129.50 K(+92.7%) | $423.50 K(-19.6%) |
| Apr 2009 | - | $67.20 K(-48.0%) | $526.60 K(-22.1%) |
| Jan 2009 | - | $129.30 K(+32.6%) | $675.80 K(-25.0%) |
| Oct 2008 | $900.80 K(+255.9%) | $97.50 K(-58.1%) | $900.80 K(-0.8%) |
| July 2008 | - | $232.60 K(+7.5%) | $907.70 K(+18.9%) |
| Apr 2008 | - | $216.40 K(-38.9%) | $763.10 K(+30.2%) |
| Jan 2008 | - | $354.30 K(+239.4%) | $586.30 K(+131.6%) |
| Oct 2007 | $253.10 K(+1146.8%) | $104.40 K(+18.6%) | $253.10 K(+70.2%) |
| July 2007 | - | $88.00 K(+122.2%) | $148.70 K(+145.0%) |
| Apr 2007 | - | $39.60 K(+87.7%) | $60.70 K(+187.7%) |
| Jan 2007 | - | $21.10 K | $21.10 K |
| Oct 2006 | $20.30 K | - | - |
FAQ
- What is Lexaria Bioscience annual revenue?
- What is the all time high annual revenue for Lexaria Bioscience?
- What is Lexaria Bioscience annual revenue year-on-year change?
- What is Lexaria Bioscience quarterly revenue?
- What is the all time high quarterly revenue for Lexaria Bioscience?
- What is Lexaria Bioscience quarterly revenue year-on-year change?
- What is Lexaria Bioscience TTM revenue?
- What is the all time high TTM revenue for Lexaria Bioscience?
- What is Lexaria Bioscience TTM revenue year-on-year change?
What is Lexaria Bioscience annual revenue?
The current annual revenue of LEXX is $464.28 K
What is the all time high annual revenue for Lexaria Bioscience?
Lexaria Bioscience all-time high annual revenue is $1.36 M
What is Lexaria Bioscience annual revenue year-on-year change?
Over the past year, LEXX annual revenue has changed by +$238.08 K (+105.25%)
What is Lexaria Bioscience quarterly revenue?
The current quarterly revenue of LEXX is $84.00 K
What is the all time high quarterly revenue for Lexaria Bioscience?
Lexaria Bioscience all-time high quarterly revenue is $494.50 K
What is Lexaria Bioscience quarterly revenue year-on-year change?
Over the past year, LEXX quarterly revenue has changed by -$67.30 K (-44.48%)
What is Lexaria Bioscience TTM revenue?
The current TTM revenue of LEXX is $464.30 K
What is the all time high TTM revenue for Lexaria Bioscience?
Lexaria Bioscience all-time high TTM revenue is $1.57 M
What is Lexaria Bioscience TTM revenue year-on-year change?
Over the past year, LEXX TTM revenue has changed by +$184.60 K (+66.00%)